cs.AINov 2, 2026

El Agente Fármaco: A Scalable AI Scientist for Drug Discovery

Authors: Marcel Müller, Mohammad Ghazi Vakili, Yoshihiro Ogura, Ella Ashoori, Shimeng Wang, Alessandro S. Nascimento, Eddie Calleja, Yutong Zhao, 

Organizations: Department of Chemistry, University of Toronto, Lash Miller Chemical Laboratories, 80 St. George Street, ON M5S 3H6, Toronto, Canada · Vector Institute for Artificial Intelligence, 661 University Ave. Suite 710, ON M5G 1M1, Toronto, Canada · Department of Computer Science, University of Toronto, Sandford Fleming Building, 10 King’s College Road, ON M5S 3G4, Toronto, Canada · São Carlos Institute of Physics, University of São Paulo, São Carlos, Brazil · 

Abstract

Computational drug discovery offers a growing range of tools for proposing and evaluating molecules, but combining them and deciding what to do next still requires substantial expert effort. Here, we introduce El Agente Fármaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows. The agentic harness selects scientific tools, reviews their results, and adjusts subsequent steps to the target and the user's objectives. Our approach centers on a shared scientific memory: Fármaco Atlas, which stores molecules, structures, and results together with their provenance -- a record of how they were obtained. The agent uses targeted database queries to retrieve the evidence needed for each decision. A single request can launch calculations for an entire collection of molecules, without requiring a separate LLM decision for every compound. This design limits the information the model must process as screening collections grow, while keeping the underlying results available for inspection and further analysis. The integrated tools support molecule generation, prediction of binding and molecular properties, and searches for compounds available for purchase. In a retrospective comparison with an expert-led campaign, the agent proposed chemically distinct candidates with competitive docking scores and higher calculated drug-likeness under explicitly imposed selection criteria. In a 22-task benchmark against plain tool calls and Codex, the agent achieved the highest observed mean model-judged score, with lower median cumulative token use and peak context. Fármaco provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.

Figures & tables

Appendix figures & tables21 assets

Supplementary material from the paper’s appendix.

Appendix

Explore similar work

Oct 12, 2026

MADDIE: Multi-Agent Drug Discovery Engine

Drug discovery remains a resource-intensive and time-consuming process, involving billions of dollars and a decade of development to advance a drug to market. While many in silico tools have accelerated this process, operating them still demands substantial time, effort, and expertise from medicinal chemists. Autonomous systems built on Large Language Models (LLMs) have emerged as a promising solution, yet current designs limit their performance. Existing single-agent systems scale poorly to long-horizon, multi-step, and realistic tasks, whereas multi-agent systems typically execute predefined workflows that cannot capture the iterative, non-linear nature of a real drug discovery campaign. Here, we present MADDIE, a multi-agent drug discovery engine. It comprises a central agent, Orchestrator, and four specialized worker agents: HitIdentifier, LeadOptimizer, Synthesizer, and Evaluator, each representing a critical step in a drug discovery campaign. Under Orchestrator's orchestration and coordination, these worker agents are composed into flexible workflows, enabling MADDIE to adapt its strategy and navigate the drug discovery pipeline end-to-end. Across 50 protein targets, MADDIE produces molecules satisfying key property requirements and their synthesis routes, outperforming existing agentic systems, generative models, and general-purpose LLMs by a wide margin. Our analysis reveals how these agents collaborate and that MADDIE can employ different strategies across targets to achieve the campaign's goal, while still being efficient in time and tokens. Together, they demonstrate MADDIE as a low-cost, effective, and efficient autonomous engine for accelerating drug discovery. Code and dataset is available via https://github.com/ninglab/MADDIE.
Oct 5, 2026

From Benchmark to Bench: Can Agents Survive Real-World Drug Discovery?

Agentic systems increasingly coordinate molecular-design tools, but it is unclear which layer of the stack limits outcomes on real projects. We developed MAGI, an open modular agent that authors objectives, launches and monitors optimization, interprets structure--activity relationships, and revises its strategy accordingly. MAGI generates molecules either directly through the LLM or by delegating to REINVENT 4, with scoring services interchangeable behind a common contract. We tested it across nine retrospective lead-optimization campaigns from three pharmaceutical companies, replayed under fixed temporal cutoffs. Both routes produced valid structures: LLM proposals stayed closer to local chemistry and reached comparable or higher primary activity in fewer operations, whereas REINVENT explored broader chemical space. Whether a campaign met its objective depended on the predictive models, not on the generation route: attainment followed model accuracy on the chemistry proposed, dropping once that chemistry moved outside the model's applicability domain. Separately, a blinded evaluation asked whether the MAGI's output could pass as expert work: chemists were not able to discriminate agentic proposals from held-out compounds, and judged the SAR reasoning broadly plausible yet incomplete. Together, these results position MAGI as a coordination layer pluggable into existing computational chemistry workflows. The ceiling on real projects, however, remains currently set by scorer applicability rather than by tool orchestration.
Oct 3, 2026

Toward a Locally Deployable Agentic Co-Scientist: Small-Model Planning for Early-Stage Drug Discovery

Early-stage computational drug discovery requires coordinating heterogeneous scientific tools across multi-step workflows. We present a lightweight, tool-augmented framework in which a locally deployable compact language model plans calls to 18 modular tools. A Unified Molecular Schema maintains shared molecular records, while a plug-in interface supports tool replacement and extension. We construct 1,263 manually refined query-plan pairs through workflow-graph path coverage and apply LoRA fine-tuning to three compact model families. Under the query-level split, all fine-tuned models generate fully parseable and schema-compliant plans on 47 held-out cross-group queries. Llama 3.2-3B achieves a tool-selection F1 of 0.998, sequence exact match of 0.979, and argument F1 of 0.960. Under the stricter workflow-grouped split, which excludes identical ordered tool sequences across partitions, sequence exact match reaches 0.452 to 0.548, highlighting the remaining difficulty for compact models in generating complete workflow paths unseen during training. These results demonstrate the feasibility of compact, locally deployable planning while identifying compositional generalization as an important direction for further improvement.